The final report of the 2016 RxTrace U.S. Pharma Traceability Survey, sponsored by Frequentz is now available. Download the full free report here. With this year’s survey we attempted to get a glimpse of the progress toward the next deadlines of the Drug Supply Chain Security Act (DSCSA) from drug manufacturers, repackagers, wholesale distributors, 3PLs and dispensers. Each of those different types of respondents were asked a different set of questions that were pertinent to their segment and their regulatory requirements under the DSCSA.
Take a close look at the results. They reveal that some progress has been made toward manufacturer and wholesale distributor deadlines. They also indicate that respondents are optimistic about their ability to meet their next deadline, even though there is concern about the progress of contract partners.
The report includes the full results from 24 specific questions in graphical and text forms, and it extracts 13 specific findings from the results. Here is one example (click on the image to enlarge):
From the responses to Question 9 it appears that the major problems are related to the lack of understanding or expertise within the contract partner’s organization. But it appears that no one is having trouble with a contract partner who doesn’t believe it will be necessary for them to deploy compliant solutions. That’s good news! It is also good news that only 11% of these respondents cited money as a problem—either that the contract partner does not have enough, or that, and the manufacturer/repackager is not willing to pay for the upgrades.